Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating ...

Despite being off-patent for many years, Humalog and other insulin brands continue to make high sales, with Lilly booking around $3 billion from its product last year, $1.8 billion of which was ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Which insulin brands are in shortage and why? Earlier this year, Eli Lilly reported temporary shortages of Humalog and insulin lispro in 10-milliliter vials. The company said new regulations had ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

The Tempo pen is currently compatible with three of Lilly's insulin products, including Humalog and Lyumjev, both insulin lispro-based, and insulin glargine brand Basaglar. "Despite technological ...

Administered either as a tablet or liquid drops, typically in a daily dosage two separate brand name medications: Mounjaro ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...